GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Smith & Nephew PLC (LSE:SN.) » Definitions » Intrinsic Value: Projected FCF

Smith & Nephew (LSE:SN.) Intrinsic Value: Projected FCF

: £7.71 (As of Today)
View and export this data going back to 1951. Start your Free Trial

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-19), Smith & Nephew's Intrinsic Value: Projected FCF is £7.71. The stock price of Smith & Nephew is £9.668. Therefore, Smith & Nephew's Price-to-Intrinsic-Value-Projected-FCF of today is 1.3.

The historical rank and industry rank for Smith & Nephew's Intrinsic Value: Projected FCF or its related term are showing as below:

LSE:SN.' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.25   Med: 1.71   Max: 2.22
Current: 1.25

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Smith & Nephew was 2.22. The lowest was 1.25. And the median was 1.71.

LSE:SN.'s Price-to-Projected-FCF is ranked better than
60.82% of 342 companies
in the Medical Devices & Instruments industry
Industry Median: 1.685 vs LSE:SN.: 1.25

Smith & Nephew Intrinsic Value: Projected FCF Historical Data

The historical data trend for Smith & Nephew's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Smith & Nephew Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.19 8.16 8.63 8.24 7.71

Smith & Nephew Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.63 - 8.24 - 7.71

Competitive Comparison

For the Medical Devices subindustry, Smith & Nephew's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Smith & Nephew Price-to-Projected-FCF Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Smith & Nephew's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Smith & Nephew's Price-to-Projected-FCF falls into.



Smith & Nephew Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Smith & Nephew's Free Cash Flow(6 year avg) = £360.85.

Smith & Nephew's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*360.84571428571+4121.43*0.8)/873.000
=7.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Smith & Nephew  (LSE:SN.) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Smith & Nephew's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=9.668/7.7119382266862
=1.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Smith & Nephew Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Smith & Nephew's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Smith & Nephew (LSE:SN.) Business Description

Traded in Other Exchanges
Address
Hatters Lane, Building 5, Croxley Park, Watford, Hertfordshire, GBR, WD18 8YE
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 41% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Smith & Nephew (LSE:SN.) Headlines

No Headlines